References
- 1Montagna MT, Caggiano G, Lovero G, De Giglio O, Coretti C, Cuna T, et al. Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project). Infection. 2013; 41:645-53.
MontagnaMTCaggianoGLoveroGDe GiglioOCorettiCCunaTet alEpidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project)Infection2013 4164553
- 2Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D. The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis. 2012;73:293-300.
AzieNNeofytosDPfallerMMeier-KriescheHUQuanSPHornDThe PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012Diagn Microbiol Infect Dis2012 73293300
- 3Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Clin Microbiol Infect. 2006;25:419-25.
FalagasMEApostolouKEPappasVDAttributable mortality of candidemia: a systematic review of matched cohort and case-control studiesClin Microbiol Infect2006 2541925
- 4Shorr AF, Gupta V, Sun X, Johannes RS, Spalding J, Tabak YP. Burden of early-onset candidemia: analysis of culture-positive bloodstream infections from a large U.S. database. Crit Care Med. 2009; 37:2519-26.
ShorrAFGuptaVSunXJohannesRSSpaldingJTabakYPBurden of early-onset candidemia: analysis of culture-positive bloodstream infections from a large U.S. databaseCrit Care Med2009 37251926
- 5Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin McrobiolRev. 2007; 20:133-63.
PfallerMADiekemaDJEpidemiology of invasive candidiasis: a persistent public health problemClin McrobiolRev2007 2013363
- 6Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol. 2010;48:1366-77.
PfallerMADiekemaDJGibbsDLNewellVAEllisDTullioVet alResults from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusionJ Clin Microbiol2010 48136677
- 7Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr., Calandra TF, Edwards JE, Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48:503-35.
PappasPGKauffmanCAAndesDBenjaminDK
Jr CalandraTFEdwardsJEJr et alClinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of AmericaClin Infect Dis2009 4850335 - 8Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol. 2012;50:2846-56.
PfallerMADiekemaDJProgress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012J Clin Microbiol2012 50284656
- 9Clinical and Laboratory Standards Institute. CLSI document M27-A3: Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. 3rd ed. Wayne: Clinical and Laboratory Standards Institute; 2008.
Clinical and Laboratory Standards Institute CLSI document M27-A3: Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard3rdWayneClinical and Laboratory Standards Institute2008 - 10Lee SC, Lo HJ, Fung CP, Lee N, See LC. Disk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazole. J Microbiol Immunol Infect. 2009; 42:148-53.
LeeSCLoHJFungCPLeeNSeeLCDisk diffusion test and E-test with enriched Mueller-Hinton agar for determining susceptibility of Candida species to voriconazole and fluconazoleJ Microbiol Immunol Infect2009 4214853
- 11Sims CR, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L. Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp. J Clin Microbiol. 2006; 44: 2105-8.
SimsCRPaetznickVLRodriguezJRChenEOstrosky-ZeichnerLCorrelation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida sppJ Clin Microbiol2006 4421058
- 12Matar MJ, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob Agents Chemother. 2003; 47: 1647-51.
MatarMJOstrosky-ZeichnerLPaetznickVLRodriguezJRChenERexJHCorrelation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazoleAntimicrob Agents Chemother2003 47164751
- 13Chen CY, Huang SY, Tsay W, Yao M, Tang JL, Ko BS, et al. Clinical characteristics of candidaemia in adults with haematological malignancy, and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2001–2010. Int J Antimicrob Agents. 2012; 40: 533-8.
ChenCYHuangSYTsayWYaoMTangJLKoBSet alClinical characteristics of candidaemia in adults with haematological malignancy, and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2001–2010Int J Antimicrob Agents2012405338
- 14Clinical and Laboratory Standards Institute. CLSI document M44-A. Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline. 2nd ed. Wayne: Clinical and Laboratory Standards Institute; 2004.
Clinical and Laboratory Standards Institute CLSI document M44-A. Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline 2ndWayneClinical and Laboratory Standards Institute2004 - 15Foongladda S, Sakulmaiwatana P, Petlum P, Vanprapar N. Candida species, genotypes and antifungal susceptibility of Candida isolates from blood samples of patients at the largest tertiary care hospital in Thailand during 1999-2002. J Med Assoc Thai. 2004; 87:92-9.
FoongladdaSSakulmaiwatanaPPetlumPVanpraparNCandida species, genotypes and antifungal susceptibility of Candida isolates from blood samples of patients at the largest tertiary care hospital in Thailand during 1999-2002J Med Assoc Thai2004 87929
- 16Tan TY, Tan AL, Tee NW, Ng LS. A retrospective analysis of antifungal susceptibilities of Candida bloodstream isolates from Singapore hospitals. Ann Acad Med Singapore. 2008; 37:835-40.
TanTYTanALTeeNWNgLSA retrospective analysis of antifungal susceptibilities of Candida bloodstream isolates from Singapore hospitalsAnn Acad Med Singapore2008 3783540
- 17Amran F, Aziz MN, Ibrahim HM, Atiqah NH, Parameswari S, Hafiza MR, et al. In vitro antifungal susceptibilities of Candida isolates from patients with invasive candidiasis in Kuala Lumpur Hospital, Malaysia. J Med Microbiol. 2011; 60:1312-6.
AmranFAzizMNIbrahimHMAtiqahNHParameswariSHafizaMRet alIn vitro antifungal susceptibilities of Candida isolates from patients with invasive candidiasis in Kuala Lumpur Hospital, MalaysiaJ Med Microbiol2011 6013126
- 18Xiao M, Fan X, Chen SC, Wang H, Sun ZY, Liao K, et al. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance. J Antimicrob Chemother. 2015; 70:802-10.
XiaoMFanXChenSCWangHSunZYLiaoKet alAntifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillanceJ Antimicrob Chemother2015 7080210
- 19Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol. 2013; 51:2571-81.
PfallerMAMesserSAWoosleyLNJonesRNCastanheiraMEchinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistanceJ Clin Microbiol2013 51257181
- 20Vandenbossche I, Vaneechoutte M, Vandevenne M, De Baere T, Verschraegen G. Susceptibility testing of fluconazole by the NCCLS broth macrodilution method, E-test, and disk diffusion for application in the routine laboratory. J Clin Microbiol. 2002; 40:918-21.
VandenbosscheIVaneechoutteMVandevenneMDe BaereTVerschraegenGSusceptibility testing of fluconazole by the NCCLS broth macrodilution method, E-test, and disk diffusion for application in the routine laboratoryJ Clin Microbiol2002 4091821